The disconnect between US cannabis fundamentals and stock performance
There is a disconnect between fundamental performance and stock performance for U.S. cannabis companies, resulting in compressing valuations for those operations.
There is a disconnect between fundamental performance and stock performance for U.S. cannabis companies, resulting in compressing valuations for those operations.
With adult-use cannabis newly legal in New York, entrepreneurs and developers on the prowl for real estate are scooping up everything from a former prison site to greenhouses – and there are even plans for a sprawling “cannabis campus.”
Merger and acquisition activity is sizzling in Pennsylvania, with more than $400 million worth of deals announced since March alone, as local cannabis businesses cash out and multistate operators seek or expand footholds in the rapidly growing mid-Atlantic market.
Illinois-based multistate operator Green Thumb Industries is expanding into Virginia with a definitive agreement to acquire medical marijuana company Dharma Pharmaceuticals.
New York recently enacted an adult-use marijuana law that many industry experts believe has the most robust provisions yet for including minorities, women, war veterans and struggling farmers in the state’s newest industry.